Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.

Merck KGaA’s antibody-drug conjugate (ADC), precemtabart tocentecan, has shown to be safe and tolerable in a Phase Ib trial.

The global Biomarkers Market, valued at US$58.07 billion in 2024 stood at US$62.39 billion in 2025 and is projected to advance at a resilient CAGR of 10.8% from 2025 to 2030, culminating in a ...

The National Legal and Policy Center, a right-wing advocacy and watchdog group, had asked the company to revisit its DEI ...

Merck has seen its shares drop 10.6% over the past month, underperforming both its industry and the broader market. Earnings ...

Merck KGaA (OTC:MKGAF) is seeking worldwide regulatory approval for its CSF-1R inhibitor pimicotinib following robust Phase ...

In the latest instalment of a long-running dispute, the Court of Appeal has recently upheld the High Court judge's view on ...

Merck KGaA (Merck) is filing for global regulatory approvals of its CSF-1R inhibitor pimicotinib after it met the primary and ...

Merck KGaA has shown off data that fueled its $85 million bet on a late-phase treatment for a rare, locally aggressive tumor.

Merck KGaA said pimicotinib, an orally administered inhibitor for tenosynovial giant cell tumor, delivered positive results in a late-phase study. The German life-sciences and electronics company said ...

Merck beats Q1 2025 estimates despite Gardasil sales drop, driven by Vaxneuvance, Winrevair & Welireg. Click here to find out ...